Abstract
BackgroundAnti-PD-1(L1) therapies are less efficacious in patients with EGFR-mutated non-small-cell lung cancer. However, the underlying mechanism is poorly understood.MethodsThe characteristics of T cells in EGFR-mutated and wild-type tumors were analyzed...
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have